Prospective study of cutaneous adverse effects associated with BRAF inhibitor dabrafenib and MEK inhibitor trametinib: A study of 12 patients

被引：0
|
作者：
Lacroix, Jean-Philip [1 ]
Wang, Beatrice [2 ]
Mihalciouiu, Catalin [2 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Royal Victoria Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3300
引用
收藏
页码：AB68 / AB68
页数：1
相关论文
共 50 条
  • [21] Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients
    Vanneste, L.
    Wolter, P.
    Van den Oord, J. J.
    Stas, M.
    Garmyn, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (01) : 61 - 68
  • [22] A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers
    Ioka, T.
    Ikeda, M.
    Fukutomi, A.
    Morizane, C.
    Kasuga, A.
    Takada, R.
    Takahashi, H.
    Todaka, A.
    Okusaka, T.
    Creasy, C.
    Gorman, S.
    Felitsky, D.
    Kawamura, T.
    Kobayashi, M.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S464 - S464
  • [23] Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)
    Cebon, Jonathan S.
    Flaherty, Keith
    Weber, Jeffrey S.
    Kim, Kevin
    Infante, Jeffrey R.
    Daud, Adil
    Hamid, Omid
    Kefford, Richard
    Schuchter, Lynn Mara
    Sosman, Jeffrey Alan
    Sznol, Mario
    Sharfman, William Howard
    Gonzalez, Rene
    Andrews, Miles Cameron
    Dronca, Roxana Stefania
    Long, Georgina
    Little, Shonda M.
    Sun, Peng
    Patel, Kiran
    McWilliams, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial
    Robert, Caroline
    Shen, Shensi
    Allard, Delphine
    Fernandez, Ana Arance
    Dutriaux, Caroline
    de Jong, Egbert
    Squires, Matthew
    Grob, Jean-Jacques
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    Atreya, Chloe Evelyn
    Van Cutsem, Eric
    Bendell, Johanna C.
    Andre, Thierry
    Schellens, Jan H. M.
    Gordon, Michael S.
    McRee, Autumn Jackson
    O'Dwyer, Peter J.
    Muro, Kei
    Tabernero, Josep
    van Geel, Robin
    Sidhu, Roger
    Greger, James G.
    Rangwala, Fatima A.
    Motwani, Monica
    Wu, Yuehui
    Orford, Keith W.
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma
    Yanagihara, Ryan T.
    Tom, Elysse S.
    Seitzman, Gerami D.
    Saraf, Steven S.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (7-8) : 2005 - 2009
  • [27] Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study
    Picca, Alberto
    Birzu, Cristina
    Berzero, Giulia
    Sanchez-Pena, Paola
    Gaboriau, Louise
    Vidil, Faustine
    Lenglet, Timothee
    Tafani, Camille
    Ricard, Damien
    Psimaras, Dimitri
    Bihan, Kevin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (11) : 4941 - 4949
  • [28] Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
    Corcoran, Ryan Bruce
    Atreya, Chloe Evelyn
    Falchook, Gerald Steven
    Infante, Jeffrey R.
    Hamid, Omid
    Messersmith, Wells A.
    Daud, Adil
    Kwak, Eunice Lee
    Ryan, David
    Kurzrock, Razelle
    Sun, Peng
    Cunningham, Elizabeth Ann
    Orford, Keith W.
    Motwani, Monica
    Bai, Yuchen
    Patel, Kiran
    Venook, Alan P.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study
    De Alcubierre, Dario
    Gkasdaris, Grigorios
    Mordrel, Margaux
    Joncour, Anthony
    Briet, Claire
    Almairac, Fabien
    Boetto, Julien
    Mouly, Celine
    Larrieu-Ciron, Delphine
    Vasiljevic, Alexandre
    Villa, Chiara
    Sergeant, Camille
    Ducray, Francois
    Feuvret, Loic
    Chanson, Philippe
    Baussart, Bertrand
    Raverot, Gerald
    Jouanneau, Emmanuel
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2024, 191 (02) : 251 - 261
  • [30] Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours
    Amita Patnaik
    Anthony Tolcher
    Kyriakos P. Papadopoulos
    Murali Beeram
    Drew Rasco
    Theresa L. Werner
    John W. Bauman
    Anita Scheuber
    Donna S. Cox
    Bela R. Patel
    YanYan Zhou
    Mohammed Hamid
    Daniel Schramek
    Sunil Sharma
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 491 - 500
12345